JPWO2020252129A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020252129A5 JPWO2020252129A5 JP2021573404A JP2021573404A JPWO2020252129A5 JP WO2020252129 A5 JPWO2020252129 A5 JP WO2020252129A5 JP 2021573404 A JP2021573404 A JP 2021573404A JP 2021573404 A JP2021573404 A JP 2021573404A JP WO2020252129 A5 JPWO2020252129 A5 JP WO2020252129A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- medicament according
- miglastat
- administered
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025076158A JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859904P | 2019-06-11 | 2019-06-11 | |
| US62/859,904 | 2019-06-11 | ||
| PCT/US2020/037174 WO2020252129A1 (en) | 2019-06-11 | 2020-06-11 | Methods of treating fabry disease in patients having renal impairment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076158A Division JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022536687A JP2022536687A (ja) | 2022-08-18 |
| JPWO2020252129A5 true JPWO2020252129A5 (https=) | 2023-06-20 |
| JP2022536687A5 JP2022536687A5 (https=) | 2023-06-20 |
| JP7677910B2 JP7677910B2 (ja) | 2025-05-15 |
Family
ID=71950725
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573404A Active JP7677910B2 (ja) | 2019-06-11 | 2020-06-11 | 腎機能障害を有する患者のファブリー病を治療する方法 |
| JP2025076158A Pending JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076158A Pending JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220313670A1 (https=) |
| EP (1) | EP3982962A1 (https=) |
| JP (2) | JP7677910B2 (https=) |
| KR (1) | KR20220019796A (https=) |
| CN (1) | CN114423427A (https=) |
| AR (1) | AR120055A1 (https=) |
| AU (2) | AU2020291002A1 (https=) |
| BR (1) | BR112021024886A2 (https=) |
| CA (1) | CA3141226A1 (https=) |
| CL (1) | CL2021003280A1 (https=) |
| EA (1) | EA202290024A1 (https=) |
| IL (1) | IL288677A (https=) |
| MX (1) | MX2021015352A (https=) |
| PH (1) | PH12021553102A1 (https=) |
| TW (1) | TW202112372A (https=) |
| WO (1) | WO2020252129A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2573498T3 (es) | 2006-05-16 | 2016-06-08 | Amicus Therapeutics, Inc. | Opciones de tratamiento para la enfermedad de Fabry |
| SI3470077T1 (sl) | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| CA3224537C (en) | 2017-05-30 | 2025-09-09 | Amicus Therapeutics, Inc. | USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE |
| CA3090496C (en) | 2018-02-06 | 2024-03-26 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| EP4282472A3 (en) | 2018-08-20 | 2024-02-21 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
| EP3851105B1 (en) | 2019-08-07 | 2026-03-04 | Amicus Therapeutics, Inc. | Migalastat for use in treating fabry disease in patients having a mutation in the gla gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| AU2008232614A1 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of Fabry disease using pharmacological chaperones |
| EP2150254A4 (en) * | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES |
| SI3470077T1 (sl) | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| CN103974619B (zh) * | 2011-03-11 | 2017-02-15 | 阿米库斯治疗学公司 | 治疗法布里病的给药方案 |
| AR109103A1 (es) * | 2016-07-19 | 2018-10-31 | Amicus Therapeutics Inc | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert |
| EP3565583A4 (en) * | 2017-01-05 | 2020-12-02 | Protalix Ltd. | TREATMENT DIET FOR THE TREATMENT OF FABRY'S DISEASE USING STABILIZED ALPHA-GALACTOSIDASE |
| PT4324522T (pt) * | 2017-05-30 | 2026-03-13 | Amicus Therapeutics Inc | Métodos de tratamento de pacientes com fabry tendo insuficiência renal |
| AR111971A1 (es) * | 2017-05-30 | 2019-09-04 | Amicus Therapeutics Inc | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal |
| CA3224537C (en) * | 2017-05-30 | 2025-09-09 | Amicus Therapeutics, Inc. | USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE |
-
2020
- 2020-06-11 AR ARP200101648A patent/AR120055A1/es unknown
- 2020-06-11 WO PCT/US2020/037174 patent/WO2020252129A1/en not_active Ceased
- 2020-06-11 EP EP20751716.0A patent/EP3982962A1/en active Pending
- 2020-06-11 CN CN202080042938.3A patent/CN114423427A/zh active Pending
- 2020-06-11 US US17/618,277 patent/US20220313670A1/en active Pending
- 2020-06-11 JP JP2021573404A patent/JP7677910B2/ja active Active
- 2020-06-11 KR KR1020227000878A patent/KR20220019796A/ko active Pending
- 2020-06-11 EA EA202290024A patent/EA202290024A1/ru unknown
- 2020-06-11 CA CA3141226A patent/CA3141226A1/en active Pending
- 2020-06-11 TW TW109119640A patent/TW202112372A/zh unknown
- 2020-06-11 BR BR112021024886A patent/BR112021024886A2/pt unknown
- 2020-06-11 MX MX2021015352A patent/MX2021015352A/es unknown
- 2020-06-11 AU AU2020291002A patent/AU2020291002A1/en not_active Abandoned
- 2020-06-11 PH PH1/2021/553102A patent/PH12021553102A1/en unknown
-
2021
- 2021-12-05 IL IL288677A patent/IL288677A/en unknown
- 2021-12-09 CL CL2021003280A patent/CL2021003280A1/es unknown
-
2025
- 2025-05-01 JP JP2025076158A patent/JP2025131572A/ja active Pending
-
2026
- 2026-01-29 AU AU2026200618A patent/AU2026200618A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020196750A (ja) | 線維症を処置するためのセニクリビロック併用療法 | |
| EP1741446B1 (en) | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | |
| KR101868991B1 (ko) | 피라졸 유도체 및 그 의약용도 | |
| US11033532B2 (en) | Uses of benzimidazole derivative for nocturnal acid breakthrough | |
| PT2043637E (pt) | Métodos e medicamentos para administração de ibuprofeno | |
| RU2070042C1 (ru) | Средство для лечения слабоумия, обусловленного цереброваскулярной патологией и болезнью альцгеймера | |
| BR112014023795B1 (pt) | Uso de inibidores de ccr3 | |
| JPH10510241A (ja) | Ｉｉ型糖尿病治療薬剤としてのケトコナゾール、および、その関連物質の使用法 | |
| JP2015537009A (ja) | 痛風の治療におけるブシラミンの使用 | |
| TW200843741A (en) | Pharmaceutical composition | |
| JPWO2020252129A5 (https=) | ||
| CN115397431A (zh) | 用于治疗涉及全身过度炎症反应的病症的eclitasertib | |
| JPWO2015129750A1 (ja) | 慢性腎臓病の進行抑制又は改善剤 | |
| US12090125B2 (en) | Combination therapy | |
| JPH0352815A (ja) | 血管内血液凝固症候群の治療剤 | |
| JPWO2004002473A1 (ja) | 血糖コントロール用医薬組成物 | |
| JPH1017478A (ja) | 潰瘍性大腸炎の予防又は治療剤 | |
| WO2024041633A1 (zh) | 一种稠环嘧啶类化合物的用途 | |
| BRPI0906158B1 (pt) | composição farmacêutica de liberação modificada compreendendo doxofilina e processo para a preparação de composição | |
| CN115715191B (zh) | 排尿症状治疗剂 | |
| CN105663152A (zh) | 三乙酰基-3-羟基苯基腺苷在制备改善胰岛素抵抗及相关疾病中的应用 | |
| CN110831590A (zh) | 含有培马贝特的医药 | |
| JP4384435B2 (ja) | くしゃみ抑制組成物 | |
| US20060121034A1 (en) | Treatment for alzheimer's disease and related conditions | |
| CA2753754C (en) | Methods for treating schizophrenia |